N. Katsumata

Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) (2009)

Katsumata, N., Watanabe, T., Minami, H., Aogi, K., Tabei, T., Sano, M., ...

Background: This randomized, multicenter, phase III trial compared doxorubicin plus cyclophosphamide (AC), single-agent docetaxel (D), and an alternating regimen of AC and docetaxel (AC–D) as...

A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: A Japanese Cooperative Study (2000)

Katsumata, N., Tsunematsu, R., Tanaka, K., Terashima, Y., Ogita, S., Hoshiai, H., ...

Background: This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in Japanese patients with advanced ovarian cancer. Patients and methods: Docetaxel was administered at...

Augmentation of vecuronium-induced neuromuscular block during sevoflurane anaesthesia: comparison with balanced anaesthesia using propofol or midazolam (1999)

Suzuki, T., Munakata, K., Watanabe, N., Katsumata, N., Saeki, S., Ogawa, S.

Cerebral metastasis in patients with uterine cervical cancer (1998)

Ikeda, S, Yamada, T, Katsumata, N, Hida, K, Tanemura, K, Tsunematu, R, ...

Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment (1998)

Yamamoto, N, Katsumata, N, Watanabe, T, Omuro, Y, Ando, M, Narabayashi, M, ...

Clinicopathological factors predicting retroperitoneal lymph node metastasis and survival in endometrial cancer (1998)

Tang, X, Tanemura, K, Ye, W, Ohmi, K, Tsunematsu, R, Yamada, T, ...

Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan (1996)

Katsumata, N, Matsuno, Y, Nakayama, H, Takenaka, T, Kobayashi, Y, Takeyama, K, ...

A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.

Ando, M., Watanabe, T., Sasaki, Y., Ying, D. F., Omuro, Y., Katsumata, N., ...

To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of...

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

Katsumata, N, Noda, K, Nozawa, S, Kitagawa, R, Nishimura, R, Yamaguchi, S, ...

The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients...

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

Tokuda, Y, Watanabe, T, Omuro, Y, Ando, M, Katsumata, N, Okumura, A, ...

We conducted a phase I pharmacokinetic dose escalation study of a recombinant humanized anti-p185HER2 monoclonal antibody (MKC-454) in 18 patients with metastatic breast cancer refractory to...

Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus

Kasamatsu, T, Onda, T, Katsumata, N, Sawada, M, Yamada, T, Tsunematsu, R, ...

Docetaxel: an alternative taxane in ovarian cancer

Katsumata, N

The taxanes paclitaxel and docetaxel are potent chemotherapeutic agents that block tubulin depolymerisation, leading to the inhibition of microtubule dynamics and cell cycle arrest. Although...